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A B S T R A C T   
MicroRNAs (miRNAs) are a group of small non-coding RNAs that post-transcriptionally control expression of 
genes by targeting mRNAs. miRNA alterations partake in the establishment and progression of different types of 
human cancer. Consequently, expression profiling of miRNA in human cancers has correlations with cancer 
detection, staging, progression, and response to therapies. Particularly, amplification, deletion, abnormal pattern 
of epigenetic factors and the transcriptional factors that mediate regulation of primary miRNA frequently change 
the landscape of miRNA expression in cancer. Indeed, changes in the quantity and quality of miRNAs are 
associated with the initiation of cancer, its progression and metastasis. Additionally, miRNA profiling has been 
used to categorize genes that can affect oncogenic pathways in cancer. Here, we discuss several circulating 
miRNA signatures, their expression profiles in different types of cancer and their impacts on cellular processes.   
1. Introduction 
Cancer is a complex genetic defect comprising structural and 
expression abnormalities of coding and non-coding transcripts. The first 
indication of miRNAs correlation with cancer was revealed in 2002 
through detection of recurrent deletions in a miRNA-coding region in 
half of patients with B cell chronic lymphocytic leukemia [1]. Since that 
time, it has been shown within the scientific community that miRNAs 
dysregulation is highly influential and partakes in cancer development 
and progression [2]. Moreover, several miRNAs have been detected that 
have tumor suppresser or oncogenic roles [3–5]. It is now clear that the 
genomic complexity of the neoplastic cells is much more than estimated. 
After these significant findings, the characterization and cloning of 
small, non-coding RNAs with ~22 nt length has led to the recognition of 
more than 1000 miRNAs. miRNAs play fundamental regulatory roles in 
shaping cellular activity, including development, differentiation, pro-
liferation, apoptosis, and genomic stability [6] through specific 
base-pairing with target transcript and/or protein molecules, and tran-
scriptional and post-transcriptional regulation of their expression [7]. 
GENCODE data (v.29) has listed around 2600 mature miRNAs 
encoded by 1872 annotated miRNA precursor genes in human [8]. 
Functions of many of these miRNAs are still unknown [9]. A single 
miRNA might bind with up to hundred different transcripts [8,10]. 
Moreover, a specific mRNA may attach to various miRNAs, either 
simultaneously or in a circumstance-dependent manner [11]. miRNAs 
have direct contribution in oncogenesis in diverse tissues since they 
function as tumor suppressors (miR-15a and miR-16–1) or oncogenes 
(miR-17–92 cluster and miR-155) [12,13]. Moreover, miRNAs have 
been regarded as markers for genetic susceptibility to cancers [14,15]. 
Molecular analysis showed that the genomic aberrations such as chro-
mosomal rearrangements, deletions, and mutations or genomic ampli-
fications impact on the activity of miRNAs [13]. 
In addition to their effects in the cellular functions in cancer cells, 
miRNAs can regulate function of other cells in the tumor niche. Extra-
cellular miRNAs can affect intercellular communications cooperating 
with stromal cells and constituents of the extracellular matrix to create a 
suitable microenvironment for cancer cells to grow and escape from 
immune responses [16]. For instance, miR-200c decreases expressions 
of PTEN and FOG2, inducing PI3K/Akt cascade and leading to amass-
ment of myeloid-derived suppressor cells and inhibition of immune 
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response in the tumor milieu [17]. Moreover, macrophages have been 
shown to secrete miRNA-containing exosomes to enhance invasiveness 
of breast cancer cells. Notably, miR-223, a miRNA specific for 
interleukin-4-induced macrophages has been among these miRNAs 
[18]. In addition, exosomal transfer of miR-144 and miR-126 has an 
important role in the establishment of a new metabolic system in favor 
of cancer progression [19]. 
2. Biogenesis of miRNAs 
The mechanism of biosynthesis of miRNA is schematically presented 
in (Fig. 1). It involves a complex protein process in which the Argonaute 
protein family members, RNA pol II, and the RNase III enzymes (Drosha 
and Dicer) participate [7]. After being transcribed by RNA pol II, the 
long precursor (pri-miRNA) is used to produce another transcript with 
hairpin structure an approximately 70 nt, namely the precursor-miRNA 
(pre-miRNA) [20,21]. The pre-miRNA then experiences additional 
processing steps catalyzed by Dicer [22,23]. This cleavage event results 
in production of an approximately 22-nt miRNA duplex comprising of 
mature miRNA [24]. Later, the mature double-stranded RNA binds to 
Argonaute proteins producing RNA-induced silencing complex (RISC) 
[25] which subsequently controls the translation of target mRNA with 
complementary sequences in the 3′ untranslated region (UTR). miRNAs 
binding with other regions, including open reading frame (ORF) or 
5′UTR of the mRNA and gene promoters have been described as well 
[26–29]. A schematic illustration of miRNA biogenesis can be seen in 
Fig. 1. 
3. Mechanisms of abnormal expression of miRNA in neoplasms 
Over the last decades, dysregulation of miRNAs expression has been 
observed in diverse neoplams. In spite of significant progress in under-
standing and knowing the basic mechanism of miRNA biosynthesis, less 
is recognized about the mechanisms that control miRNA biogenesis and 
how this process might be dysregulated in the oncogenic process. Ac-
cording to the finding of the recent studies, the mechanisms of miRNA 
dysregulation primarily involves the amplification or deletion of miRNA 
genes, abnormal activity of transcription factors, epigenetic dysregula-
tion, and defects in the genes in the miRNA biogenesis pathway [13]. 
Furthermore, competitive endogenous RNAs (ceRNAs) might decrease 
intracellular miRNA level. 
3.1. Amplification or deletion of miRNA genes 
miRNAs are encoded in various regions of the mammalian genome. 
Around half of miRNAs are transcribed from non-protein-coding re-
gions, whereas approximately 40% reside in the introns of protein- 
coding genes [30,31]. Intronic miRNAs are usually transcribed with 
their host genes, yet the pattern of intergenic miRNAs is less understood. 
Numerous miRNAs are located in neoplasm-associated genomic regions 
or common breakpoints adjacent to fragile sites [32], and in other 
genomic sites which harbors cancer-associated rearrangements. 
The earliest discovery of miRNAs role on cancer has reported that 
two clusters of miRNA genes, miR-15a and miR-16a are located within 
the 13q14.3 region which is lost in chronic lymphocytic leukemia (CLL) 
and that both genes are frequently deleted in most of CLL cases [1]. 
Moreover, the loss of both miR-15 and miR-16–1 genes is highly 
correlated to CLL, and promotes the overexpression of BCL2 and ROR1 
[33–35]. Therefore, loss of miRNAs resulted from chromosomal deletion 
or rearrangements may cause oncogenesis. Further comprehensive 
analysis revealed that both miR-143 and miR-145 genes located on 
chromosome 5q33 region are often deleted in lung cancers, resulting in 
reduced expression of both miRNAs [36]. In particular, the miR-17–92 
cluster on a translocation site has been overexpressed in T-cell acute 
lymphoblastic leukemia and induced lymphomagenesis in vivo [37]. Lin 
Zhang et al. identified high-frequency genomic abnormalities in miRNA 
loci in 227 samples of human breast cancer, ovarian cancer, and mela-
noma [38]. Overall, these results indicate that unusual expression of 
miRNA in cancer cells might be resulted from amplification or deletion 
of particular genomic sites of miRNA genes. 
3.2. Regulation of miRNAs transcription 
Expression of miRNAs is closely regulated via various transcription 
factors, so aberrant expression of miRNA in tumors may be resulted from 
dysregulation of some major transcription factors, including p53 and c- 
Myc. Several studies have shown conclusive indications that changes in 
transcriptional protein activators or suppressors lead to abnormal pri- 
miRNA transcription in human cancers. As an example, genes encod-
ing miR-34a, miR-34b, and miR-34c are directly controlled by the p53, 
indicating the impacts of the functional p53 in determining expression 
of miR-34 in neoplastic cells [39,40]. p53 is upregulated as a response to 
DNA damage and oncogenic stress, and controls the transcription of 
miR-34, which triggers apoptosis, cell cycle arrest, and cell senescence 
in different types of cancer [41]. miR-145 is also transcriptionally 
activated via over-expression of p53 to promote apoptosis [42–45]. 
RAS-responsive element-binding protein 1 (RREB1) downregulates 
miR-143/145 levels and promotes tumorigenesis [46]. p53 also controls 
expression of a variety of miRNAs, including miR-107 [47], miR-1246 
[48], and miR-605 [49,50]. miR-145 expression is also affected by 
other transcription factors, such as beta-catenin/T cell factor 4 (TCF4) 
[51], C/EBPβ, PPARγ, BRCA1 DNA repair associated (BRCA1) and 
forkhead box O (FoxO) [52–55] in human tumors. The c-myc 
proto-oncogene encodes a protein that controls the transcription of 
various genes, including non-coding and protein-coding genes [56,57]. 
Over-expression of c-myc is a critical step in various cancers and is 
correlated with abnormal expression of several genes including miRNA 
genes [58,59]. The oncogenic c-Myc protein promotes expression of 
miR-17–92 cluster by binding to E-box in the promoter of miR-17–92 
[60]. c-Myc inhibits transcriptional activity of tumor-suppressor miR-
NAs such as miR-6–15a-20–29 and let-7 [61]. Moreover, recurrent 
amplification of 13q31-q32 locus, which has the miR-17–92, is 
frequently found in lymphomas harboring MYC rearrangements, indi-
cating that the miR-17 cluster and c-Myc may work together to promote 
aggressive cancer development [62]. In hepatocellular carcinoma 
(HCC), c-Myc attaches to the conserved regions of miR-363–3p or 
miR-148a-5p promoter genes and suppresses their expression [58]. In 
turn, miR-363–3p destabilizes Myc through the direct binding and 
inhibiting ubiquitin-specific protease 28, whereas miR-148a-5p directly 
binds and suppresses Myc expression [63]. Suppression of miR-363–3p 
or miR-148a-5p promotes hepatocellular tumorigenesis by inducing G1 
to S phase progression. In addition to p53 and c-Myc, which are two 
already studied transcriptional factors, more proteins have been 
discovered as transcriptional factors that control miRNA expression. For 
example, Mef2c which motivates the proliferation of myeloid progeni-
tor, is influenced by miR-223, and the genetic ablation of Mef2c tran-
scriptional factor advantageously inhibits the progenitor expansion and 
amends the neutrophilic phenotypes [64,65]. 
3.3. Epigenetic control of miRNAs 
An eminent characteristic of cancer is epigenetic alteration. DNA 
methylation and histone tail modifications change chromatin structure. 
Epigenetic is known as meiotically and mitotically heritable gene 
expression changes that do not include DNA nucleotide alterations. The 
utmost frequent epigenetic modifications are methylation of DNA at the 
5-carbon of the cytosine and modification of histone tails (histone 
acetylation and methylation) [66,67], which are identified to have 
major impacts on the expression of human genes. Methylation of histone 
H3 lysine 9 is an important event in epigenetic control of gene expres-
sion and might be stimulated by DNA methylation [68]. Histone meth-
yltransferases have been shown to interact with other enzymes that 
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Fig. 1. Biogenesis of miRNAs has several steps: (1) Transcription by RNA polymerase II resulting in the production of long primary miRNA transcripts with diverse 
sizes (pri-miRNA). Within the nucleus, pri-miRNA is cleaved by Drosha RNase III enzyme creating a hairpin configuration known as pre-miRNA. (2) Export of pre- 
miRNA into the cytoplasm by exportin 5 and its processing by Dicer. (3) Creation of the transient 19–24 nucleotide duplex. Only the mature miRNA from the miRNA 
duplex is integrated into RISC. (4) The mature miRNA directs RISC to degrade mRNA or prompt translational suppression or translational activation. 
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modify epigenetic marks on DNA or histones [68]. Disruption of 
epigenetic mechanisms results in aberrant expression of miRNAs in 
cancer cells [69,70]. Fig. 2 depicts the DNA-methylation patterns of 
miRNAs in normal and tumor cells. 
3.3.1. DNA Methylation 
Methylation of DNA typically happens in all vertebrate cells at 
carbon-5 of cytosine ring in CpG dinucleotides. This process is mediated 
by DNA methyltransferase (DNMT) family, using S-adenosyl-methionine 
(SAM) as methyl-donor. Methylation of CpG human promoter genes are 
usually inhibited, while unmethylated CpG promoters can be expressed. 
Studies have shown that numerous miRNAs target each mRNA, and it is 
predicted that up to 30% of human protein-coding genes are controlled 
by miRNAs [73]. Similar to protein-coding genes, miRNAs are prone to 
epigenetic alterations. For example, Zhenhai et al. has discovered that 
intronic miR-340–5p expression was epigenetically downregulated by 
promoter DNA methylation of its host gene in multiple myeloma [74]. 
Saito and his colleagues showed that 17 out of 313 human miRNAs in 
T24 bladder cancer cells are over-expressed more than 3-folds after 
concurrent treatment with suppressors of DNA methylation of DNA and 
histone acetylation. miR-127 is one of these miRNAs which is located in 
a CpG island and its expression is extremely promoted in the tumor cells 
after treatment with 5-Aza-2′-deoxycytidine in combination with 4-phe-
nylbutyric acid, decreasing levels of its target BCL6 proto-oncogene 
[75]. These findings show that both DNA demethylation and histone 
deacetylase inhibition could induce the expression of such types of 
miRNAs. Another study stated that DNA hypomethylation causes a 
release of miR-124a silencing in colorectal cancer cell lines through 
transcriptional inactivation by CGI methylation [76]. miR-34b/c and 
miR-148a also undergo certain hypermethylation-associated silencing in 
metastatic cell lines from head and neck cancer, colon cancer and mel-
anoma cells. Furthermore, hypermethylation-associated silencing of 
these miRNAs reduced tumor growth and inhibited metastasis formation 
in vivo [77]. Hyper-methylation of miR-124, miR-125, miR-126, 
miR-127, miR-148a, miR-193a, miR-132, miR-133a-3p, miR-137 and 
miR-34b/c has been found in breast cancer cells [78–82]. In addition, 
let-7a, miR-9, miR-10b, miR-152, miR-200, miR-195/497 family, and 
miRNAs at the DLK1-DIO3 imprinted locus harbor similar epigenetic 
marks [83–85]. Down-regulation through methylation process of some 
miRNA such as miR-149 was described in chemoresistant breast cancer 
patients [86]. Furthermore, a number of miRNAs which suppress pro-
liferation, invasion, and migration of cancer cells, were downregulated 
due to promoter hypermethylation in different types of cancer. Among 
these miRNAs are let-7a, miR-9, miR-34b/c, miR-338–3p, miR-596, 
miR-125a-5p, miR-375, miR-27b-3p, miR-495–3p, miR-490–3p and 
miR-124a in gastric cancer [87–97], let-7a, miR-9, miR-124 s, 
miR-125a-5p, miR-192, miR-615–5p, miR-1247, miR-142–3p, 
miR-148a, miR-132, miR-200, miR-152, miR-17 and miR-92 in 
pancreatic cancer [98–109], miR-9, let-7a, miR-191, miR-203, miR-335, 
miR-137, miR-142, miR-148a, miR-375, miR-195, miR-183, miR-497, 
miR-124, miR-125, miR-378, miR-639 in HCC [110–120], and let-7a, 
miR-107, miR-203a, miR-1258, miR − 9, miR-107, miR-124–3p, 
miR-125b-5p, miR-127–5p, miR-129–5p, miR-130b, miR-132–3p, 
miR-137, miR-148a-3p, miR-339–3p, miR-375, miR-34a, miR-203a, 
miR-34b/c, miR-191–5p, miR-193a-5p, miR-193a-3p, miR-196, 
miR-508–3p, miR-424/503 cluster in ovarian cancer [121–132]. 
Fig. 2. A schematic model of DNA methylation-dependent miRNAs in normal & cancer cells. Aberrant promoter DNA methylation pattern in tumorigenesis. In 
normal cells, CpG dinucleotides (lollipops) of promoter intergenic or intragenic miRNAs associated CpG island are usually unmethylated (blue lollipops) which could 
lead to a euchromatin histone configuration allowing availability of TFs, HATs, HMT and RNA polymerase complex, for miRNA transcription, and thereby tran-
scription could occur. Whilst, in tumor cells, promoter of intergenic or intragenic miRNAs associated CpG islands is aberrantly hypermethylated (red lollipops) via 
DNMT that associated with recruitment of HMT, MBD and HDAC, leading to a compact chromatin configuration, and thereby availability of transcription complex is 
blocked, resulting in miRNA silencing. TF: Transcription factor; Pol II: RNA polymerase II; HDAC: Histone deacetylase; MBD: Methyl-CpG-binding domain protein; 
TAF: TBP-associated factor; TBP: TATA-binding protein; Co-Act: Co-activator; HMT: Histone methyltransferase; DNMT: DNA methyltransferase; HAT: Histone 
acetyltransferase [71,72]. (For interpretation of the references to colour in this figure, the reader is referred to the web version of this article.) 
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It has been shown by numerous studies that there is a significant 
change in the expression profile of the miRNA not just in tumor samples 
but also in the blood and urine of patients with bladder neoplasm [133, 
134]. Bladder carcinogenesis and chemotherapy resistance are closely 
related to miRNA expression dysregulations [135]. Various miRNAs 
such as let-7, miR-145, miR-152, miR-10a, miR-129, miR-148, miR-193, 
miR-935, miR-137, miR-126, miR-200 and miR-205 showed signifi-
cantly higher methylation levels in bladder cancer patients [136–144]. 
miR-137, miR-124, miR-2, miR-3 and miR-9 were specifically methyl-
ated in urine specimens of bladder cancer [137,138]. Recent studies 
interpreted that aberrant DNA methylation usually leads to dysregula-
tion of miRNAs in cancer, and methylation pattern of certain miRNAs 
may be an important marker for cancer diagnosis and prognosis. Such 
dysregulation of miRNA signature results in genome-wide epigenetic 
abnormalities [145]. For example, hypermethylation of DNA sequences, 
histone modifications, and abnormal miRNA expression patterns have 
been regarded as three main epigenetic alterations that contribute in 
leukemia progression [146]. 
Promoters of let-7a, miR-9, miR-124–3p and miR-125 genes are 
silenced by aberrant CpG methylation in breast, ovarian, gastric, lung, 
pancreatic, and bladder cancers. Silencing of miRNA genes allows up- 
regulation of essential products of the oncogene, such as epidermal 
growth factor (EGF) and cyclin G1 (CCNG1) [147], which lead to pro-
gression of tumor and cancer invasiveness. 
Hyper-methylation in the promoter region of miRNA-137 has been 
found in more than ten different types of cancer, which is contributed to 
transcriptional repression of miRNA-137 and affects the regulation of 
various cellular processes in tumor cells, such as remodeling of the 
chromosome by direct targeting of the EZH2 [148,149], cell cycle pro-
gression by targeting Cdc42 and Cdk6 [150], metabolism of tumor 
glutamine by targeting ASCT2 [151] and TRIM24 [152], chromatin 
remodeling by targeting LSD1 [153]. 
Tumor-suppressor miR-34 gene is also hypermethylated at the CpG 
site in the promoter region in numerous tumors, and its silencing has 
affected various cellular process by targeting NOTCH1 [154] and CD44 
[155]. This process also affects cellular senescence via modulation of 
telomerase activity through targeting FoxM1 and c-Myc [156,157], and 
apoptosis by direct targeting BCL2 protein apoptosis regulator [158]. 
3.3.2. Histone modifications 
The key protein components of chromatin are histones, a series of 
small, highly conserved proteins. Histone tail methylation and acetyla-
tion are the two main modifications of histone proteins in chromatin 
that play a key role in its regulation in response to different cellular 
signals. The main biological processes including DNA replication, gene 
expression, and repair of DNA damage are regulated by histone proteins 
modifications, which occur at specific residues on histone N-terminal 
tails [159]. Histone deacetylation gave rise to a more compact chro-
matin state and inhibited gene transcription, while acetylation of 
lysine-tails in histone protein was associated with a more relaxed 
chromatin structure and activation of gene transcription [160]. Scott 
et al. were the first group who showed the evidence of miRNA deregu-
lation due to the modification of histone proteins in tumor cells in 2006. 
They found 27 aberrantly expressed miRNAs in breast cancer after 
treating SKBr3 breast cancer cells with an HDACs inhibitor [161]. Other 
investigators have shown that HDAC inhibitor affects miRNA expression 
in different types of cancer [69, 160–164]. Due to the overexpression of 
HDACs (HDAC1, HDAC2, and HDAC3), miR-29b, miR-15a, and miR-16 
are epigenetically repressed in mantle cell lymphoma (MCL) and CLL. 
Indeed, HDAC inhibition restores the expression of miR-29b, miR-15a, 
and miR-16 in CLL cells, and was associated with declining levels of 
MCL-1 and triggered CLL apoptosis [165]. 
Furthermore, in HCC cells, overexpression of histone deacetylases 
(HDAC1–3) decreases expression of miRNA-449. miR-449 attaches to c- 
MET mRNA to decrease its levels, reducing proliferation, and promoting 
apoptosis of liver cancer cells [166]. Notably, histone acetylation, in 
some settings, is involved in oncomiR activation in cancer. For instance, 
in HCC, miR-224 is commonly overexpressed. It has also been reported 
that miR-224 expression is positively associated with histone acetylase 
EP300 protein in HCC patients [167]. 
3.4. Abnormal function of genes in the biogenesis of miRNA pathway 
In addition to genomic alterations, transcription factors, and alter-
ations of epigenetics mechanisms, defects in the miRNA biogenesis 
system influence the expression of miRNA and enhance oncogenesis. 
The altered expression of Dicer and Drosha, two main enzymes in the 
miRNA maturation is linked to down-regulation of miRNAs in numerous 
kinds of human cancer including breast cancer [168,169]. In vitro and 
genetically modified human cell lines proved that DICER1 and DROSHA 
mutations affect miRNA processing via several routes. 
Mutations in DICER1 generally impair miRNAs biogenesis from the 
5’-arm of pre-miRNA hairpins, whereas DROSHA mutations impede 
miRNA processing via a dominant-negative manner. Mutations in both 
DICER1 and DROSHA impair tumor suppressor miRNA expression, such 
as let-7 family [170]. Additionally, pre-miRNAs are processed into 
mature miRNAs after exported via the nuclear membrane to the cyto-
plasm. The export of pre-miRNAs is mediated by exportin 5 and its 
cofactor [171]. Thus, a genetic defect in exportin-5 sequesters 
pre-miRNAs in the nucleus, decreases miRNA processing, and reduces 
miRNA-target suppression. The mutant form of exportin 5 does not have 
the C-terminal region that participates in forming the ternary structure 
complex (pre-miRNA/XPO5/Ran-GTP), thus pre-miRNAs amass in the 
nucleus of cancer cells [172]. 
3.5. The competitive endogenous RNA (ceRNA) 
The interference between non-coding and coding RNA molecules 
characterizes a new way of gene regulation. The principal regulators of 
gene expression are miRNAs. They regulate mRNA expression through 
the direct binding on their miRNA Response Element (MRE) sites [173]. 
Besides, protein-coding RNA transcripts and other non-coding RNAs can 
attach to miRNAs through MRE sites. Therefore, they are known as 
miRNA sponge or ceRNA, since they compete with mRNA target for 
miRNA binding [174]. 
The ceRNA hypothesis proposed that in addition to mRNA, se-
quences of circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), 
and pseudogenes contain MREs, inhibiting normal miRNA targeting 
activity on mRNA. Recent studies have found that ceRNAs are correlated 
with several diseases, including cancer [175–177]. Changes in the 
expression levels of ceRNA have to be large enough to reduce or over-
come the miRNA repression on competing ceRNAs. This is characterized 
by RNA transcripts “switched” off or on at the transcriptional level in 
physiological or pathological conditions. A pseudogene of the PTEN 
tumor suppression gene is PTENP1. Its mRNA sequence, near to 3’-UTR, 
is highly homologous to the similar region in PTEN, and this charac-
teristic of PTENP1 indicates that it could use as a ceRNA of PTENP gene 
[174]. Several studies showed the significance of the ceRNA mechanism 
in cancer cells [175, 178–180]. Tay et al. stated ceRNA regulation of 
PTEN in prostate cancer and glioblastoma cells, detecting candidates 
through mutually targeted MRE enrichment analysis [179]. They had 
observed that mRNA sharing the most miRNA binding sites that were 
coexpressed with PTEN would potentially bind PTEN-targeting miRNAs 
and relieve their repression of PTEN. Along with the variety of bioin-
formatics and experimental approaches used in the above-mentioned 
studies, these attributes of PTEN may notify the future identification 
of ceRNA cancer-relevant regulatory networks and their pathological 
dysregulation. Most notably, ceRNA function is a well-established route 
of participation of circular RNAs (circRNAs) in the neoplastic trans-
formation. These covalently enclosed single-stranded RNAs have been 
shown to act as sponges for miRNAs, thus sequestering miRNAs and 
attenuating their functional roles. [181]. For instance, ciRS-7 has tens of 
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conserved binding sites for miR-7 [182], thus having high efficiency for 
sponging this miRNA. Moreover, circHIPK3 can serve as a molecular 
sponge for several miRNAs [181], including those being involved in the 
neoplastic transformation. 
4. Onco-miRs and tumor-suppressor-miRNAs 
Genome expression studies propose interesting different perspectives 
on participation of miRNAs in human neoplasms. miRNAs have been 
associated with different cellular functions including controlling cellular 
proliferation, differentiation and programing of cell death [183]. It was 
found that miRNAs can act as either tumor suppressor genes by targeting 
oncogenic mRNAs or oncomiRs, probably through several mechanisms, 
such as elimination of tumor suppressor proteins. For example, 
miR-125b exerts as a tumor suppressor effects in various solid tumors 
because its expression decreases the expression of LIPA, PCTP, ACCS1, 
HK2 GSS, IKZF4, SCD1, and TP53 [184]. On the other hand, miR-125b is 
an oncomiR in most of human leukemias such as AML [185], AMKL 
[186], CML [187] and ALL [188]. Indeed, miR-125b mostly exerts its 
oncogenic role by repression of hematopoietic differentiation factors 
(PRDM1, CBFB, IRF4, IL10RA, IL2RB) or by direct targeting the 
metastasis gene promoters (LIN28B, ARID3B, MMP13), metastasis in-
hibitors (TP53INP1, STARD13) and pro-apoptotic factors (BAK1,TP53, 
BMF, MAPK14, BBC3) [189–192]. Another instance of this fact is given 
by the miR-155 which possesses an oncogenic role in many hemato-
logical and solid malignancies, so it is considered as an oncomiR [193]. 
High levels of miR-155 directly targets SHIP1 and IL-6 pathway, a 
negative regulator of B-cell differentiation promoting the accumulation 
of apoptosis-resistant pre-BI cells [194]. However, despite its strong 
oncogenic effects, Levati et al. found that miR-155 impedes cancer 
proliferation and induces apoptosis process in several melanoma cell 
lines in which it acts as tumor suppressor, due to silencing of SKI gene 
[195]. Similarly, Qin et al. and Li et al. showed that miR-155 acts as 
tumor suppressor in ovarian and gastric cancer-initiating cells by 
directly targeting CLDN1 and SMAD2, respectively [195,196]. 
Variation of genomic miRNA within target sites may be a major 
source for genetic differences in cancer risk. Numerous studies have 
revealed that polymorphisms and mutations lead to functional loss or 
modification of existing miRNA target sites [193,194] and the formation 
of new miRNA binding sites [197]. Even within a single cancer type, the 
variance of a miRNA being oncogenic or tumor-suppressive is high-
lighted in this set of studies. 
5. miRNA profiling as a new clinical tool 
Since various studies proved participation of miRNAs in carcino-
genesis and metastasis, miRNAs are currently being investigated to have 
a great role in prognostic and diagnostic methods. It was proved that a 
unique signature of thirteen miRNAs was correlated with disease pro-
gression in CLL [198]. Further investigation showed that expression of 
numerous miRNAs could accurately distinguish ALL cases with frequent 
translocations from other subjects [199]. Additionally, low expression of 
let-7a-2 and high expression of miR-155 were related with poor clinical 
outcome in lung cancer [200]. 
Numerous studies indicated that miRNAs can be biomarkers in 
prognosis and diagnosis [199,201]. Carme et.al. stated that the level of 
miR-210 expression was conversely associated with disease-free survival 
proposing that miR-210 might be an independent prognostic factor for 
early breast cancer patients [202]. Intriguingly, a recent study using 
microarray profiling to investigate the patterns of miRNA expression 
showed the association between upregulation of miR-21 and advanced 
clinical stage, lymph node involvement, and patient poor survival [203]. 
Moreover, downregulation of miR-126 and miR-335 expression was 
strongly associated with metastatic regression in breast cancer patients 
[204]. miRNAs have been found as biomarkers in biopsy specimens. In 
addition, more recently, various reports recommended that free 
circulating miRNAs are measurable in plasma or serum and the levels of 
tumor-associated miRNAs increased in multiple tumors such as prostate 
cancer [205], lung cancer [206], colorectal cancer [207], and ovarian 
cancer [208] and other cancers[209,210]. These results indicate that 
blood-based miRNAs might emerge as innovative source of biomarkers 
for diagnosis of different types of cancer. 
6. miRNAs as drugs or therapeutic targets 
Many preclinical and in vitro studies have inhibited oncomiRs or 
reintroduced oncosuppressive miRNAs in cancer cells, proving that 
these therapies are effective in inhibition of cell migration and prolif-
eration or enhancement of cell death. This indicates that these miRNAs 
(oncomiRs or oncosuppressor miRNAs) could be used as drugs or ther-
apeutic targets. The advantage of modulating miRNA expression instead 
of genes is their ability to target various genes and pathways simulta-
neously. Also, one oncosuppressive miRNA might strongly decrease the 
risk of resistance to therapy by targeting critical genes. Conversely, the 
miRNA effect on the expression of various genes may also have clinically 
significant side effects due to inaccurate target effects. Besides, miRNA 
delivery as anticancer therapies is one of the big issues, because a system 
might be necessary in which miRNAs should be delivered to every tumor 
cells, otherwise untreated cells could help tumor recurrence. 
Moreover, re-expression of oncosuppressor miRNAs might be 
blocked the progression of cancer in vivo [211]. In vivo model systems 
have shown the efficacy of this method in suppression of cancer cells 
proliferation and stimulation of apoptosis without toxicity. Oncosup-
pressor miRNAs induction has also been shown to be used in epigenetic 
control. Different drugs have been used for remodeling of chromatin to 
inhibit methylation of DNA and deacetylation of histone, amending 
epigenetic alterations in cancer cells [75]. This understanding recom-
mends that miRNAs delivery could be an essential therapeutic strategy. 
Recently, inhibition of miR-124 and prevention of DEN-induced HCC in 
animals support application of this kind of anticancer therapeutic ap-
proaches [212]. There are several systems for miRNA delivery as ther-
apies, such as antisense oligonucleotide inhibitors of miRNAs, 
double-stranded oligonucleotides, anti-miRs, and miR-mimics to 
restore miRNA function. These innovative miRNAs therapeutic systems 
open the potential for a novel therapeutics class and recommend a 
unique cancer treatment approach via modulating the entire biological 
pathways. 
7. Conclusion 
It is evident that miRNAs participate in tumorigenesis and control 
the progression of human neoplasms. While many improvements have 
been made in the knowledge of miRNA involvement in cancer, further 
understanding of existing form and biological function is necessary, as 
many questions still need to answer. The greatest challenge for the 
future will be the concept of cancer-specific miRNA signature that could 
be used for miRNA-based cancer therapeutic and diagnostic approaches. 
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